Kidney protection and SGLT2i: What do we know?
Video navigation menu
- Epidemiology of CKD 00:32
- Treatment options for DKD 02:23
- Newer treatment options: GLP-1RAs and SGLT2 inhibitors 06:12
- Ongoing SGLT2i trials enrolling CKD/DKD patients 11:18
- EASD/ADA consensus report on choice of second-line therapy 12:07
Which statement is true about renal outcomes of recent SGLT2i trials?
- A. Decline in eGFR was larger in macroalbuminuria patients on canagliflozin in CREDENCE
- B. In EMPA-REG OUTCOME, patients with macroalbuminuria had renal benefit with empagliflozin
- C. Use of SGLT2i in EMPA-REG OUTCOME, DECLARE-TIMI 58 and CANVAS resulted in CV benefit, but not renal benefit
- D. A meta-analysis of four SGLT2i trials showed heterogeneity of renal outcomes with SGLT2i use
This lecture by Mark Cooper was part of the EBAC-accredited symposium "Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i" held during the virtual ERA EDTA 2020 meeting.
Prof. Mark Cooper, MD - Inaugural Head of the Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.